Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program

Bone Marrow Transplantation

Volumn 47, Issue 1, 2012, Pages 15-17

  Chabannon, C ^a,b   Pamphilon, D ^b,c   Vermylen, C ^b,d   Gratwohl, A ^e   Niederwieser, D ^f   McGrath, E ^b   Lamers, C ^g   Lanza, F ^h   Slaper Cortenbach, I ⁱ   Madrigal, A ^j   Apperley, J ^b,k  

^a INSERM   (France)

^b JACIE Accreditation Office   (Spain)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h CREMONA HOSPITAL   (Italy)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j ROYAL FREE HOSPITAL   (United Kingdom)

^k HAMMERSMITH HOSPITAL   (United Kingdom)

more..

Author keywords

accreditation; cell collection; cell processing; clinical transplant; quality management; SCT

Indexed keywords

ACCREDITATION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EUROPE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; REGISTER; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME;

ACCREDITATION; EUROPEAN UNION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NATIONAL HEALTH PROGRAMS; REGISTRIES; SOCIETIES, MEDICAL; TISSUE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855747786     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.32     Document Type: Article

References (15)

1. Pamphilon D, Apperley JF, Samson D, Slaper-Cortenbach I, McGrath E. JACIE accreditation in 2008: demonstrating excellence in stem cell transplantation. Hematol Oncol Stem Cell Ther 2009; 2: 311-319.
2. LeMaistre CF, Loberiza Jr FR. What is quality in a transplant program? Biol Blood Marrow Transplant 2005; 11: 241-246. (Pubitemid 40450750)
3. Gratwohl A, Baldomero H. Trends of hematopoietic stem cell transplantation in the third millennium. Curr Opin Hematol 2009; 16: 420-426.
4. Gratwohl A, Baldomero H, Frauendorfer K, Rocha V, Apperley J, Niederwieser D. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant 2008; 41: 687-705. (Pubitemid 351587034)
5. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A et al. Hematopoietic stem cell transplantation: a global perspective. Jama 2010; 303: 1617-1624.
6. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007; 39: 71-87. (Pubitemid 46085226)
7. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009; 43: 275-291.
8. Apperley J. Just another cost increasing exercise (JACIE)? Bone Marrow Transplant 2004; 34: 835-838. (Pubitemid 39562133)
9. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, deWitte T et al. Impact of JACIE accreditation on outcome after haematopoietic stem cell transplantation: an EBMT megafile registry based analysis. Bone Marrow Transplant [Abstract]. 2010; 45 (Suppl 2): S63 (Abstract).
10. Afolalu B, Troidle L, Osayimwen O, Bhargava J, Kitsen J, Finkelstein FO. Technique failure and center size in a large cohort of peritoneal dialysis patients in a defined geographic area. Perit Dial Int 2009; 29: 292-296.
11. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the acute leukemia and pediatric disease working parties of the European blood and marrow transplant group. Blood 2010; 115: 3437-3446.
12. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735. (Pubitemid 16124386)
13. Stem Cell Trialist's Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074-5087.
14. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-2971.
15. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and post grafting immune suppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629. (Pubitemid 36182543)